European Journal of Cancer (2013) 49, 1287–1296

Available at www.sciencedirect.com

SciVerse ScienceDirect

journal homepage: www.ejcancer.info

A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update ☆,☆☆,☆☆☆

Cora N. Sternberg [a,*], Robert E. Hawkins [b], John Wagstaff [c], Pamela Salman [d], Jozef Mardiak [e], Carlos H. Barrios [f], Juan J. Zarba [g], Oleg A. Gladkov [h], Eunsik Lee [i], Cezary Szczylik [j], Lauren McCann [k], Stephen D. Rubin [k], Mei Chen [k], Ian D. Davis [l]

[a] *Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy*
[b] *Cancer Research UK Department of Medical Oncology, University of Manchester and Christie Hospital NHS Foundation Trust, Manchester, UK*
[c] *The South West Wales Cancer Institute, Singleton Hospital, Swansea, UK*
[d] *Division of Medical Oncology and Hematology, Fundación Arturo López Pérez, Santiago, Chile*
[e] *National Oncological Institute, Klenová, Bratislava, Slovakia*
[f] *Oncology Research Unit, Oncology Service, PUCRS School of Medicine, Porto Alegre, Brazil*
[g] *Centro Médico San Roque, Tucumán, Argentina*
[h] *Chelyabinsk Regional Oncology Center, Chelyabinsk, Russian Federation*
[i] *Department of Urology, Seoul National University College of Medicine, Seoul, South Korea*
[j] *Department of Oncology, Military Institute of Medicine, Warsaw, Poland*
[k] *GlaxoSmithKline, Collegeville, PA, USA*
[l] *Joint Austin-Ludwig Oncology Unit, Ludwig Institute for Cancer Research, Austin Health, Melbourne, Australia*

Available online 12 January 2013

KEYWORDS
Renal cell carcinoma
Pazopanib
Overall survival
Rank-preserving structural failure time model
Inverse probability of censor weighting

Abstract ***Background:*** In this randomised phase III study (VEG105192; NCT00334282), pazopanib previously demonstrated statistically and clinically meaningful improvement of progression-free survival versus placebo in patients with advanced/metastatic renal cell carcinoma (mRCC). Final overall survival (OS) and updated safety results are now reported.
Methods: Treatment-naive or cytokine-pretreated mRCC patients ($n = 435$) stratified and randomised (2:1) to pazopanib 800 mg daily or placebo, were treated until disease progression, death or unacceptable toxicity. Upon progression, placebo patients could receive pazopanib

☆ *Previous Publication:* Portions of the data were presented at the 2011 ASCO Genitourinary Cancers Symposium (abstract 313, published in J Clin Oncol Volume 29, Supplement 7, 2011) and the 2010 ESMO Congress (abstract LBA22, published in Ann Oncol Volume 21, Supplement 8, 2010).

☆☆ Clinical Trials Registration: NCT00334282.

☆☆☆ *Funding.* GlaxoSmithKline.

* *Corresponding author at:* Department of Medical Oncology, San Camillo and Forlanini Hospitals, Circonvallazione Gianicolense 87, 00152 Rome, Italy. Tel.: +39 06 5870 4356; fax: +39 06 5870 4317.
E-mail address: cstern@mclink.it (C.N. Sternberg).

0959-8049/$ - see front matter
http://dx.doi.org/10.1016/j.ejca.2012.12.010

through an open-label study. Final OS in the intent-to-treat population was analysed using a stratified log-rank test. Rank-preserving structural failure time (RPSFT) and inverse probability of censoring weighted (IPCW) analyses were performed post-hoc to adjust for crossover.
Findings: The difference in final OS between pazopanib- and placebo-treated patients was not statistically significant (22.9 versus 20.5 months, respectively; hazard ratio [HR] = 0.91; 95% confidence interval [CI], 0.71–1.16; one-sided $P = .224$). Early and frequent crossover from placebo to pazopanib and prolonged duration of crossover treatment confounded the OS analysis. In IPCW analyses, pazopanib decreased mortality (HR = 0.504; 95% CI, 0.315–0.762; two-sided $P = .002$). Similar, albeit non-significant, results were obtained in RPSFT analyses (HR = 0.43; 95% CI, 0.215–1.388; two-sided $P = .172$). Since the last cutoff, cumulative exposure to pazopanib increased by 30%. The pazopanib safety profile showed no new safety signals or changes in the type, frequency and severity of adverse events.
Interpretation: Although no significant difference in OS was observed in this study, extensive crossover from placebo to pazopanib confounded final OS analysis. Post-hoc analyses adjusting for crossover suggest OS benefit with pazopanib treatment for mRCC patients.

1. Introduction

Renal cell carcinoma (RCC) accounts for 80%–85% of kidney cancers.[1] Approximately 80% of RCC patients present with clear-cell or predominantly clear-cell histology.[2,3] In the United States (US), new kidney cancer cases and deaths in 2010 were estimated as 58,240 and 13,040, respectively.[4] In Europe, new kidney cancer cases and deaths in 2008 were estimated as 88,400 and 39,300, respectively.[5]

The development of novel therapies targeting tumour angiogenesis and mammalian target of rapamycin (mTOR) pathways has significantly improved clinical outcomes in patients with advanced RCC. Since 2005, six targeted agents, sunitinib, sorafenib, pazopanib, temsirolimus, everolimus and bevacizumab with interferon alfa-2a, have received regulatory approval in the US, Europe and other countries worldwide. These agents have been included in US and European treatment guidelines as front-line and/or second-line therapies for advanced RCC.[6,7]

Pazopanib (Votrient™, GlaxoSmithKline) is an oral angiogenesis inhibitor targeting vascular endothelial growth factor receptors (VEGFR)-1/-2/-3, platelet-derived growth factor receptors (PDGFR)-α/-β and stem cell factor receptor c-Kit.[8] The regulatory approval of pazopanib[9,10] was supported primarily by clinical evidence from the pivotal, randomised and double-blind, phase III study VEG105192 (clinicaltrials.gov NCT00334282) in treatment-naive or cytokine-pretreated patients with advanced and/or metastatic RCC.[11] The study demonstrated that pazopanib treatment significantly improved progression-free survival (PFS) versus placebo in the overall study population (median, 9.2 versus 4.2 months; hazard ratio [HR] = 0.46; $P < .0001$) and in the treatment-naive (median, 11.1 versus 2.8 months; HR = 0.40; $P < .0001$) and cytokine-pretreated subgroups (median, 7.4 versus 4.2 months; HR = 0.54; $P < .001$). These previously reported results are based on data obtained by May 23, 2008, for the final PFS analysis.[11] This report provides the preplanned final analysis of overall survival (OS) and updated safety results.

2. Methods

2.1. Patients

Patients with advanced and/or metastatic RCC and measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST)[12] who were treatment-naive or had received one prior cytokine-based systemic therapy were eligible. Detailed eligibility criteria and study conduct were previously described.[11]

2.2. Study design: randomisation and masking

Patients stratified by ECOG PS (0 versus 1), prior nephrectomy status (yes versus no) and prior systemic treatment for advanced RCC (treatment-naive versus cytokine-pretreated) were randomised (2:1) to pazopanib 800 mg/day or matching placebo and treated until disease progression, death, unacceptable toxicity or consent withdrawal. Upon progression, patients could be unblinded and receive any available subsequent anticancer therapy at the discretion of the investigator and patient. Patients who progressed from the placebo arm had the option of receiving pazopanib via a parallel open-label extension study (VEG107769; clinicaltrials.gov NCT00387764). Eligibility criteria for this study were similar to those of the parent study except that patients with ECOG PS 2 were also eligible.

2.3. Study end-points and assessments

The primary end-point was PFS; the principal secondary end-point was OS. Other secondary end-points included objective response rate, duration of response